Parkinson’s disease is a condition in which parts of the brain become progressively damaged over many years. Symptoms of the condition usually develop gradually and are mild at first. This means it may take some time for symptoms to become noticeable. Most people associate Parkinson’s with problems with physical movement, however there are many, more subtle signs. One less common and less obvious symptom of Parkinson’s disease is trouble swallowing, known as dysphagia.
ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs